Recro Pharma, Inc. (REPH) Analysts See $-0.68 EPS on May, 10

April 17, 2018 - By Eula Gilbert

Recro Pharma, Inc. (NASDAQ:REPH) Corporate Logo
Big Money Sentiment decreased to 1.5 in Q4 2017. It has change of 0.15, from 2017Q3’s 1.65. The ratio fall due to Recro Pharma, Inc. positioning: 4 sold and 14 reduced. 7 funds bought positions and 20 increased positions. Investors holded 9.63 million in 2017Q3 but now own 9.57 million shares or 0.59% less.
Barclays Public Limited Liability Company holds 0% or 2,610 shs. 2,058 were reported by Parallax Volatility Advisers Limited Partnership. Legal & General Group Incorporated Pcl has 0% invested in Recro Pharma, Inc. (NASDAQ:REPH) for 2,026 shs. Vanguard Grp Inc reported 707,140 shs. Lyon Street Lc reported 1.12% stake. Renaissance Techs Lc invested in 0% or 122,000 shs. Jpmorgan Chase has 31,673 shs. Kingdon Cap Mngmt Limited Liability Com holds 0.16% or 259,948 shs. Cadence Management Limited Liability Corporation holds 180,715 shs. Macquarie Gru Ltd invested in 0% or 810 shs. State Common Retirement Fund has 6,800 shs. Essex Invest Management Communication Limited Liability Company owns 92,565 shs. Rhumbline Advisers accumulated 12,455 shs or 0% of the stock. Meeder Asset Mgmt has invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). Bnp Paribas Arbitrage Sa stated it has 3,690 shs.

Recro Pharma, Inc. had 7 insider sales and 0 insider purchases since December 12, 2017. This’s net activity of $3.53 million. $115,139 worth of Recro Pharma, Inc. (NASDAQ:REPH) shs were sold by SCP Vitalife Partners (Israel) II – L.P.. Berelowitz Michael sold $78,347 worth of Recro Pharma, Inc. (NASDAQ:REPH) on Friday, March 9. On Thursday, January 4 the insider SCP Vitalife Partners II LP sold $41,822.

Recro Pharma, Inc. (NASDAQ:REPH)’s quarterly earnings will be announced On May, 10., as reported by Faxor. Analysts forecast $-0.68 EPS, which is $0.26 down or 61.90 % from 2017’s $-0.42 EPS. After $-0.63 EPS report last quarter, Wall Street now sees 7.94 % negative EPS growth of Recro Pharma, Inc.. On during the last trading session the stock increased $0.47 or 4.26%, reaching $11.49.Recro Pharma, Inc. has volume of 209,723 shares. Since April 17, 2017 REPH has risen 37.47% and is uptrending. REPH outperformed the S&P500 by 25.92%.

Recro Pharma, Inc. (NASDAQ:REPH) Ratings Coverage

Total analysts of 3 have positions in Recro Pharma (NASDAQ:REPH) as follows: 3 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since November 9, 2017 according to StockzIntelligence Inc Recro Pharma has 3 analyst reports. The company rating was initiated by Oppenheimer on Tuesday, February 13. On Thursday, November 9 the rating was maintained by Roth Capital with “Buy”. On Wednesday, February 28 the rating was maintained by Piper Jaffray with “Buy”.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States.The company has $224.04 million market cap. The Company’s lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain.Last it reported negative earnings. The firm also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain.

Recro Pharma, Inc. (NASDAQ:REPH) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.